GAITHERSBURG, Md., April 13, 2017 -- OpGen, Inc. (NASDAQ:OPGN) today announced that five posters featuring its technologies will be presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) being held April 22-25, 2017 in Vienna, Austria. Among them will be a poster presentation titled “Prediction of antibiotic resistance in Escherichia Coli from resistance genes” by Dr. Terry Walker, Senior Vice President of Research and Development at OpGen. The presentation will highlight preliminary results supporting OpGen’s efforts to develop and commercialize a rapid and highly accurate test that predicts antibiotic resistance using resistance gene detection and the bioinformatics capabilities of the Acuitas Lighthouse® Knowledgebase. The OpGen booth location is 32B.
The details for the presentations at ECCMID are as follows:
Poster title: Prediction of antibiotic resistance in Escherichia coli from resistance genes
Presenter: T. Walker, OpGen
Date and time: Tuesday, April 25 from 12:54 - 12:59 pm CEST
Location: Poster Area
Poster number: #EP0938
Abstract number: #4182
Session info: Direct detection methods
Poster title: Use of the Acuitas Resistome Test to detect and type carbapenemase producing organisms (CPOs): A pilot study
Presenter: G. Vanstone, Royal Free London NHS Foundation Trust
Date and time: Saturday, April 22 from 3:30 - 4:30 pm CEST
Location: Poster Area
Poster number: #P0387
Abstract number: #6205
Session info: Detection of resistant pathogens
Poster title: Rapid outbreak detection of multi-drug resistant organisms using resistance genes profiles
Presenter: W. Chang, OpGen
Date and time: Saturday, April 22 from 8:45 am - 3:30 pm CEST
Location: Poster Area
Poster number: #EV0483
Abstract number: #5396
Session info: Resistance surveillance & epidemiology: Gram-negatives
Poster title: Evaluation of QuickFISH and the Sepsityper assays for early identification of aetiological agents in bloodstream infection in a clinical routine setting
Presenter: A. Pernestig, Systems Biology Research Centre, University of Skövde
Date and time: Monday, April 24 from 1:30 - 2:30 pm CEST
Location: Poster Area
Poster number: #P1561
Abstract number: #1166
Session info: Diagnostic microbiology
Poster title: Seven years of clinical experience with the Yeast Traffic Light PNA FISH: assay performance and implications on antifungal therapy
Presenter: V. Özenci, Karolinska University Hospital
Date and time: Sunday, April 23 from 1:30 - 2:30 pm CEST
Location: Poster Area
Poster number: #P0969
Abstract number: #5533
Session info: Diagnostic mycology I
About OpGen
OpGen, Inc. is harnessing the power of informatics and genomic analysis to provide complete solutions for patient, hospital and network-wide infection prevention and treatment. Learn more at www.opgen.com and follow OpGen on Twitter and LinkedIn.
OpGen Contact: Michael Farmer Director, Marketing 240-813-1284 [email protected] [email protected] OpGen Investor and Media Contact: MacDougall Biomedical Communications Cammy Duong 781-591-3443 [email protected]


U.S. Warns Allies Over Alleged Chinese AI IP Theft Linked to DeepSeek
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 



